ES2190799T3 - Inmunogenos peptidicos para vacunacion y tratamiento de la alergia. - Google Patents

Inmunogenos peptidicos para vacunacion y tratamiento de la alergia.

Info

Publication number
ES2190799T3
ES2190799T3 ES97905136T ES97905136T ES2190799T3 ES 2190799 T3 ES2190799 T3 ES 2190799T3 ES 97905136 T ES97905136 T ES 97905136T ES 97905136 T ES97905136 T ES 97905136T ES 2190799 T3 ES2190799 T3 ES 2190799T3
Authority
ES
Spain
Prior art keywords
treatment
allergy
vaccination
ige
peptidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905136T
Other languages
English (en)
Other versions
ES2190799T5 (es
Inventor
Franz Kricek
Beda Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26308839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2190799(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9604412.8A external-priority patent/GB9604412D0/en
Priority claimed from GBGB9617702.7A external-priority patent/GB9617702D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of ES2190799T3 publication Critical patent/ES2190799T3/es
Application granted granted Critical
Publication of ES2190799T5 publication Critical patent/ES2190799T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MOLECULAS INMUNOGENICAS QUE COMPRENDEN (A) AL MENOS UN RESTO DE UN PEPTIDO QUE MIMETIZA EL EPITOPO NATURAL SOBRE LA IGE HUMANA, RECONOCIDA POR EL ANTICUERPO MONOCLONAL ANTI IGE HUMANA BSW17, Y (B) UN RESTO CAPAZ DE RECHAZAR UNA RESPUESTA INMUNE CONTRA EL PEPTIDO. SON UTILES EN, O PARA LA PREPARACION DE, COMPOSICIONES FARMACEUTICAS, ESPECIALMENTE PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR IGE, TALES COMO ALERGIAS Y DERMATITIS ATOPICA, POR EJEMPLO, VACUNAS CONTRA LA ALERGIA.
ES97905136T 1996-03-01 1997-02-28 Inmunogenos peptidicos para vacunacion y tratamiento contra la alergia. Expired - Lifetime ES2190799T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9604412 1996-03-01
GBGB9604412.8A GB9604412D0 (en) 1996-03-01 1996-03-01 Organic compounds
GB9617702 1996-08-22
GBGB9617702.7A GB9617702D0 (en) 1996-08-22 1996-08-22 Organic compounds

Publications (2)

Publication Number Publication Date
ES2190799T3 true ES2190799T3 (es) 2003-08-16
ES2190799T5 ES2190799T5 (es) 2008-08-16

Family

ID=26308839

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97905136T Expired - Lifetime ES2190799T5 (es) 1996-03-01 1997-02-28 Inmunogenos peptidicos para vacunacion y tratamiento contra la alergia.

Country Status (24)

Country Link
US (1) US6610297B1 (es)
EP (1) EP0885244B2 (es)
JP (2) JP3421970B2 (es)
KR (2) KR100498198B1 (es)
CN (1) CN1174998C (es)
AT (1) ATE230417T1 (es)
AU (1) AU719609B2 (es)
BR (1) BR9707819A (es)
CA (1) CA2245497C (es)
CY (1) CY2457B1 (es)
CZ (1) CZ299551B6 (es)
DE (1) DE69718150T3 (es)
DK (1) DK0885244T4 (es)
ES (1) ES2190799T5 (es)
HU (1) HUP9901109A3 (es)
IL (1) IL125590A (es)
NO (1) NO321043B1 (es)
NZ (1) NZ331651A (es)
PL (1) PL187209B1 (es)
RU (1) RU2193413C2 (es)
SI (1) SI0885244T2 (es)
SK (1) SK284856B6 (es)
TR (1) TR199801722T2 (es)
WO (1) WO1997031948A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1621209A3 (en) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vaccines based on domains of chimeric immunoglobulin E peptides
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
AU2001252262B2 (en) * 2000-04-13 2006-02-02 Biolife Science Forschungs-und Entwicklungsgesellschaft m.b.H Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US6887472B2 (en) 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
ES2394293T3 (es) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
AU2002326751A1 (en) 2001-08-13 2003-03-03 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
DE50307169D1 (de) * 2002-01-15 2007-06-14 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh ORALE VAKZINIERUNG MIT DEM TUMOR-ANTIGEN-MIMOTOP Gln-Met-Trp-Ala-Pro-Gln-Trp-Gly-Pro-Asp
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
PT1629850E (pt) * 2004-08-24 2007-08-14 Nutricia Nv Composição nutricional que compreende a administração de oligossacarídeos indigeríveis
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
RU2340348C1 (ru) * 2007-04-04 2008-12-10 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения атопического дерматита
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
MX337723B (es) 2008-12-09 2016-03-15 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
RU2761431C9 (ru) * 2020-10-26 2022-04-18 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Рекомбинантный полипептид на основе аллергена пыльцы березы и аллергена яблока в качестве вакцины от аллергии

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2602443A1 (de) 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
EP0000252B1 (en) 1977-06-29 1982-02-03 Beecham Group Plc Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides
JPS5944399A (ja) 1982-09-07 1984-03-12 Takeda Chem Ind Ltd 新規ｄｎａ
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP0269455A3 (en) 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human ige fc fragment and production thereof
EP0344211A4 (en) 1987-02-20 1990-03-12 Imclone Systems Inc MONOCLONAL ANTIBODIES IN VACCINE COMPOSITIONS.
CA1336818C (en) 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
JPH07111427B2 (ja) 1987-10-13 1995-11-29 テラピン テクノロジーズ，インコーポレイテッド 免疫診断薬を製造する方法
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
SG70982A1 (en) 1990-01-23 2000-03-21 Tanox Biosystems Inc Extracellular segments of human and immunoglobulin anchoring peptides and antibodies specific therefor
EP0605410B1 (en) 1990-05-25 1995-08-16 Peptide Therapeutics Limited Immunodiagnostic assay for rheumatoid arthritis
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
DK0602126T3 (da) * 1991-08-14 2003-06-16 Genentech Inc Immunoglobulinvarianter til specifikke FC epsilon-receptorer
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
GB9125024D0 (en) 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
JPH06113881A (ja) 1992-10-07 1994-04-26 Snow Brand Milk Prod Co Ltd ヒト型モノクローナル抗ペプチド抗体及びこれをコードするｄｎａ
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994025060A1 (en) 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
WO1994026723A2 (en) 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
GB9320897D0 (en) 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
GB9324013D0 (en) 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
CN1146772A (zh) * 1994-03-28 1997-04-02 美国联合生物医学公司 用于治疗过敏反应的合成肽免疫原
US5962634A (en) 1994-07-08 1999-10-05 Thomas Jefferson University IgE antagonists
WO1996012740A1 (en) 1994-10-25 1996-05-02 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
WO1998024808A2 (en) 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
EP0955311A3 (en) 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Peptide vaccine for canine allergy
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens

Also Published As

Publication number Publication date
CY2457B1 (en) 2005-06-03
TR199801722T2 (xx) 1998-12-21
US6610297B1 (en) 2003-08-26
KR100584051B1 (ko) 2006-05-30
SI0885244T2 (sl) 2008-10-31
KR100498198B1 (ko) 2005-09-09
CZ277198A3 (cs) 1998-12-16
NO983999D0 (no) 1998-08-31
ES2190799T5 (es) 2008-08-16
HK1014962A1 (en) 1999-10-08
NZ331651A (en) 2000-01-28
SK118198A3 (en) 1999-03-12
PL187209B1 (pl) 2004-06-30
CN1213380A (zh) 1999-04-07
WO1997031948A1 (en) 1997-09-04
ATE230417T1 (de) 2003-01-15
DK0885244T4 (da) 2008-06-16
JP2000502571A (ja) 2000-03-07
AU1879697A (en) 1997-09-16
DE69718150T2 (de) 2003-08-21
EP0885244A1 (en) 1998-12-23
HUP9901109A3 (en) 1999-11-29
RU2193413C2 (ru) 2002-11-27
NO983999L (no) 1998-11-02
PL328858A1 (en) 1999-03-01
AU719609B2 (en) 2000-05-11
NO321043B1 (no) 2006-03-06
KR20050049509A (ko) 2005-05-25
BR9707819A (pt) 1999-07-27
HUP9901109A2 (hu) 1999-07-28
CN1174998C (zh) 2004-11-10
CA2245497A1 (en) 1997-09-04
SI0885244T1 (en) 2003-06-30
EP0885244B2 (en) 2008-04-16
CA2245497C (en) 2009-02-24
DE69718150D1 (de) 2003-02-06
KR19990087425A (ko) 1999-12-27
JP2003231696A (ja) 2003-08-19
EP0885244B1 (en) 2003-01-02
IL125590A0 (en) 1999-03-12
DK0885244T3 (da) 2003-04-22
DE69718150T3 (de) 2009-03-05
JP3421970B2 (ja) 2003-06-30
CZ299551B6 (cs) 2008-08-27
IL125590A (en) 2001-08-26
SK284856B6 (sk) 2006-01-05

Similar Documents

Publication Publication Date Title
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
ES2184869T3 (es) Vacuna sub-unitaria contra la infeccion por flavivirus.
DE60229979D1 (es)
Alonso et al. Effects of topical Arnica gel on post‐laser treatment bruises
AR020601A1 (es) Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c
PT900380E (pt) Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados
ES2185762T3 (es) Vacunas contra la peste.
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
FR2814958B1 (fr) Composition vaccinale
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
WO2023094713A3 (en) Coronavirus vaccine
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE50105431D1 (de) Kosmetische zubereitung mit pflanzenextrakten
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
ES2176495T3 (es) Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida.
Ricciardi et al. Immune mechanisms involved in schistosoma mansoni-Cathepsin B vaccine induced protection in mice
WO2007145760A3 (en) Anthrax compositions and methods of use and production
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
MX9801180A (es) Preparaciones antigenicas.
DE60109180D1 (de) Parietaria judaica ns-ltp-antigenvarianten, entsprechende pharmazeutische zusammensetzungen und ihre verwendung